Massalia Therapeutics
Landmark BioVentures launches spin-off biotech to tackle fibrotic, neoplastic and neovascularised conditions
May 20, 2025Research and Development Aix-Marseille University, Cardiology, Corporate, Landmark BioVentures, Massalia Therapeutics, Oncology, cardiovascular research, oncology
Landmark BioVentures and researchers at Aix-Marseille University in Marseille, France, have launched Massalia Therapeutics. Marking Landmark’s seventh company, the spin-off …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
